medigraphic.com
ISSN 0016-3813 (Impreso)

2016, Número 3

<< Anterior Siguiente >>

Gac Med Mex 2016; 152 (3)


Proteínas morfogenéticas óseas (BMP): aplicación clínica para reconstrucción de defectos en hueso

Sierra-García GD, Castro-Ríos R, Gónzalez-Horta A, Lara-Arias J, Chávez-Montes A

Idioma: Español
Referencias bibliográficas: 32
Paginas: 381-385
Archivo PDF: 91.18 Kb.


RESUMEN

Desde el descubrimiento de las proteínas morfogenéticas óseas (BMP), su uso se ha convertido en un valioso aliado para el tratamiento de defectos óseos. Estas proteínas son potentes factores de crecimiento relacionados con actividad osteogénica y angiogénica. La capacidad osteoinductora de la proteína morfogenética ósea recombinante (rhBMP) en la formación de hueso y cartílago ha sido confirmada en estudios in vitro y evaluada en ensayos clínicos controlados. Su aplicación ha sido de forma sistémica mediante inyecciones en dosis superiores a la fisiológica para obtener un efecto terapéutico. Dentro de las desventajas se observa formación ectópica de hueso o alta morbilidad en casos de fusión espinal. En esta revisión se analizan los roles de las BMP en la reparación ósea hasta su aplicación clínica. Estos hallazgos representan avances en el estudio de la regeneración ósea y muestran que la aplicación de factores de crecimiento es una promesa en la mejora de tratamientos para obtener resultados más predecibles.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Yilgor P, Sousa RA, Reis RL, Hasirci N, Hasirci V. Effect of scaffold architecture and BMP-2/BMP-7 delivery on in vitro bone regeneration. J Mater Sci Mater Med. 2010;21:2999-3008.

  2. van Baardewijk LJ, van der Ende J, Lissenberg-Thunnissen S, et al. Circulating bone morphogenetic protein levels and delayed fracture healing. Int Orthop. 2013;37:523-7.

  3. Ronga M, Fagetti A, Canton G, Paiusco E, Surace MF, Cherubino P. Clinical applications of growth factors in bone injuries: experience with BMPs. Injury. 2013;44 Suppl 1:S34-9.

  4. Xiong L, Zeng J, Yao A, et al. BMP2-loaded hollow hydroxyapatite microspheres exhibit enhanced osteoinduction and osteogenicity in large bone defects. Int J Nanomedicine. 2015;10:517-26.

  5. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 2):S151-8.

  6. Zárate-Kalfópulos B, Reyes-Sánchez A. Bone grafts in orthopedic surgery. Cir Cir. 2006;74:217-22.

  7. Bodde EW, Boerman OC, Russel FG, Mikos AG, Spauwen PH, Jansen JA. The kinetic and biological activity of different loaded rhBMP-2 calcium phosphate cement implants in rats. J Biomed Mater Res A. 2008;87: 780-91.

  8. Oryan A, Alidadi S, Moshiri A, Bigham-Sadegh A. Bone morphogenetic proteins: a powerful osteoinductive compound with non-negligible side effects and limitations. Biofactors. 2014;40:459-81.

  9. Mantripragada VP, Jayasuriya AC. Injectable chitosan microparticles incorporating bone morphogenetic protein-7 for bone tissue regeneration. J Biomed Mater Res A. 2014;102:4276-89.

  10. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893-9.

  11. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A. Bone morphogenetic proteins: a critical review. Cell Signal. 2011;23:609-20.

  12. Carreira AC, Lojudice FH, Halcsik E, Navarro RD, Sogayar MC, Granjeiro JM. Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res. 2014;93:335-45.

  13. Tsuji K, Bandyopadhyay A, Harfe BD, et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet. 2006;38:1424-9.

  14. Liu NM, Tian J, Wang WW, et al. Effect of erythropoietin on mesenchymal stem cell differentiation and secretion in vitro in an acute kidney injury microenvironment. Genet Mol Res. 2013;1:6477-87.

  15. Dhar SA, Gani NU, Butt MF, Farooq M, Mir MR. Delayed union of an operated fracture of the femoral neck. J Orthop Traumatol. 2008;9:97-9.

  16. Khanna-Jain R, Agata H, Vuorinen A, Sándor GK, Suuronen R, Miettinen S. Addition of BMP-2 or BMP-6 to dexamethasone, ascorbic acid, and β-glycerophosphate may not enhance osteogenic differentiation of human periodontal ligament cells. Growth Factors. 2010;28:437-46.

  17. Suliman S, Xing Z, Wu X, et al. Release and bioactivity of bone morphogenetic protein-2 are affected by scaffold binding techniques in vitro and in vivo. J Control Release. 2015;197:148-57.

  18. Faßbender M, Minkwitz S, Strobel C, Schmidmaier G, Wildemann B. Stimulation of bone healing by sustained bone morphogenetic protein 2 (BMP-2) delivery. Int J Mol Sci. 2014;15:8539-52.

  19. Vukicevic S, Simic P, Grgurevic L, Boroveck F, Sampath K. Systemic administration of bone morphogenetic proteins. In: Vukicevic S, Sampath K, editores. Bone morphogenetic proteins: from local to systemic therapeutics. Berlin: Birkhauser Verlag AG; 2008. p. 317.

  20. Baltzer AW, Ostapczuk MS, Stosch D, Granrath M. The use of recombinant human bone morphogenetic protein-2 for the treatment of a delayed union following femoral neck open-wedge osteotomy. Orthop Rev (Pavia). 2012;4:e4.

  21. Zimmermann G, Wagner C, Schmeckenbecher K, Wentzensen A, Moghaddam A. Treatment of tibial shaft non-unions: bone morphogenetic proteins versus autologous bone graft. Injury. 2009;40 Suppl 3:S50-3.

  22. Katanec D, Granić M, Majstorović M, Trampus Z, Pandurić DG. Use of recombinant human bone morphogenetic protein (rhBMP2) in bilateral alveolar ridge augmentation: case report. Coll Antropol. 2014;38:325-30.

  23. Kim YJ, Lee JY, Kim JE, Park JC, Shin SW, Cho KS. Ridge preservation using demineralized bone matrix gel with recombinant human bone morphogenetic protein-2 after tooth extraction: a randomized controlled clinical trial. J Oral Maxillofac Surg. 2014;72:1281-90.

  24. Ye L, Bokobza SM, Jiang WG. Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med. 2009;24:591-7.

  25. Kallioniemi A. Bone morphogenetic protein 4 -a fascinating regulator of cancer cell behavior. Cancer Genet. 2012;205:267-77.

  26. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol. 2007;171:1047-57.

  27. Klose A, Waerzeggers Y, Monfared P, et al. Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas. Neoplasia. 2011;13:276-85.

  28. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158:890-902.

  29. Tannoury CA, An HS. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014;14:552-9.

  30. Singh K, Nandyala SV, Marquez-Lara A, et al. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion. Spine J. 2013;13:1118-25.

  31. Abstracts of the 22nd Annual Meeting of the North American Spine Society, October 23-27, 2007, Austin, Texas, USA. Spine J. 2007;7(5 Suppl):1S-163S.

  32. Lykissas MG, Aichmair A, Sama AA, et al. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein- 2 augmentation: a cohort-controlled study. Spine J. 2014;14:217-24.




2020     |     www.medigraphic.com